References
- Fitzgerald C, Feichtinger W, Spona J, et al. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracept 1994; 10: 5–18
- Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 μg oestrogen. Contraception 1992; 46: 477–88
- Lammers P, Opten M Berg. Phase III clinical trial with a new oral contraceptive containing 150 μg desogestrel and 20 μg ethinylestradiol. Acta Obstet Gynecol Scand 1991; 70: 497–500
- Opten M Berg. International multicenter clinical trial of an oral contraceptive containing 20 μg ethinylestradiol and 150 μg desogestrel (Mercilon). Optimizing the Estrogen Dose in Oral Contraceptives, JR Newton, M Opten Berg. Parthenon Publishing Group, CarnforthUK 1992; 33–8
- Düsterberg B, Ellman H, Müller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol 1996; 10: 33–9
- Barbosa I C, Aguiar L F, Aldrighi J M, et al. Clinical evaluation of a new gestodene monophasic oral contraceptive preparation containing 75 μg gestodene and 20 μg ethinylestradiol. Contracept Fertil Sex 1995; 23((Suppl 9))S41
- Endrikat J, Jaques M-A, Mayerhofer M, et al. A twelvemonth comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52: 229–35
- Benedetto C. Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine. Gynecol Endocrinol 1989; 3: 71–94
- Chan W Y, Dawood M Y, Fuchs F. Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Am J Med 1981; 70: 535–41
- Åkerlund M, R0de A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinylestradiol. Br J Obstet Gynaecol 1993; 100: 832–8